Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer’s Disease
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) and diabetes mellitus (DM) are among the most pervasive and devastating disorders that afflict people throughout the world. Although typically associated with older demographics, recent epidemiologic studies have reported parallel trends in decreasing age of onset and increasing incidence of these conditions. Promising research continues to implicate the cerebrovasculature and blood-brain barrier (BBB) as playing key roles in AD pathoetiology. Similarly, complications accompanying DM, such as diabetic nephropathy/retinopathy, cardiovascular disease, and stroke, have been rooted in vascular compromise. Not surprisingly, DM is now considered a major risk factor for AD. The purpose of this review is to highlight investigations into the role of the cerebrovasculature in the development and progression of AD. We give particular attention to studies on humans and a variety of animal model systems that have demonstrated a link between BBB dysfunction and pathological changes in the brain consistent with aging and AD. Together, these studies suggest that the vascular complications associated with chronic, poorly managed DM can lead to subclinical BBB breakdown that precedes and drives the pathological changes progressing to symptomatic AD, providing a common mechanistic thread connecting these two disorders. Furthermore, this emphasizes the need to focus on the vasculature as a potential therapeutic target with the intent of limiting BBB breakdown involved in disease initiation and progression. In conclusion, AD may be more than just an associated comorbidity of DM, and instead another manifestation of the underlying vascular pathology that is common to both.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“The 99.6% failure rate for AD drugs in clinical trials has been both unfortunate and disheartening [1].”
InfluentialBrain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590 · cited 1×
“However, currently employed neuroimaging techniques fail to detect subacute or subclinical lesions/leakages with reliable and reproducible accuracy [18–20].”
The metabolic syndrome, inflammation, and risk of cognitive decline
Yaffe, K. (2004) · JAMA · doi:10.1001/jama.292.18.2237 · Cited by 1,025
Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700 · cited 1×
“Similar research in the United States, like the Rotterdam and Rochester studies, has also pointed to DM as a risk factor for AD [3, 4].”
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
How does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492
Starr, J. M. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.1.70 · Cited by 434
Hammer, C., Stepniak, B., Schneider, A., Papiol, S., Tantra, M., Begemann, M., Sirén, A.-L., Pardo, L. A., Sperling, S., Mohd Jofrry, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.110 · Cited by 342 · cited 1×
“As in AD, there is a rapidly growing body of evidence implicating a dysfunctional BBB as being responsible, at least in part, for initiating and/or propagating many conditions, including epilepsy, multiple sclerosis, Parkinson’s disease, depression, and schizophrenia [25–28].”
Mid- and Late-Life Diabetes in Relation to the Risk of Dementia
Xu, W., Qiu, C., Gatz, M., Pedersen, N. L., Johansson, B., & Fratiglioni, L. (2009) · Diabetes · doi:10.2337/db08-0586 · Cited by 284
Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study
Xu, W. L., von Strauss, E., Qiu, C. X., Winblad, B., & Fratiglioni, L. (2009) · Diabetologia · doi:10.1007/s00125-009-1323-x · Cited by 272
Alpha synuclein is transported into and out of the brain by the blood-brain barrier
Sui, Y.-T., Bullock, K. M., Erickson, M. A., Zhang, J., & Banks, W. A. (2014) · Peptides · doi:10.1016/j.peptides.2014.09.018 · Cited by 212 · cited 1×
“As in AD, there is a rapidly growing body of evidence implicating a dysfunctional BBB as being responsible, at least in part, for initiating and/or propagating many conditions, including epilepsy, multiple sclerosis, Parkinson’s disease, depression, and schizophrenia [25–28].”
Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis
Zhu, M., Wang, X., Hjorth, E., Colas, R. A., Schroeder, L., Granholm, A.-C., Serhan, C. N., & Schultzberg, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9544-0 · Cited by 204 · cited 1×
“Pro-inflammatory mediators are implicated in many studies linking aberrant and exaggerated inflammatory processes to AD [72].”
Tomimoto, H., Akiguchi, I., Suenaga, T., Nishimura, M., Wakita, H., Nakamura, S., & Kimura, J. (1996) · Stroke · doi:10.1161/01.str.27.11.2069 · Cited by 204 · cited 1×
“Contrary to the aforementioned studies and reports, there are also several studies that have failed to observe any significant differences in the extent of BBB permeability between AD and age-matched controls [47–51].”
Lack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies
Bien-Ly, N., Boswell, C. A., Jeet, S., Beach, T. G., Hoyte, K., Luk, W., Shihadeh, V., Ulufatu, S., Foreman, O., Lu, Y., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.09.036 · Cited by 198
Medeiros, R., Kitazawa, M., Passos, G. F., Baglietto-Vargas, D., Cheng, D., Cribbs, D. H., & LaFerla, F. M. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.051 · Cited by 163
Type 2 diabetes mellitus, dyslipidemia, and Alzheimer’s disease
Carlsson, C. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100012 · Cited by 109 · cited 5×
“DM and AD are also often recognized as comorbid diseases since pathological changes such as hyper-insulinemia, glucose intolerance, hyperglycemia, insulin resistance, atherosclerosis, hypertension, and adiposity are common in afflicted patients [5, 12–14].”
InfluentialDyslipidemia and Blood-Brain Barrier Integrity in Alzheimer's Disease
Bowman, G. L., Kaye, J. A., & Quinn, J. F. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/184042 · Cited by 100
Hüttenrauch, M., Brauß, A., Kurdakova, A., Borgers, H., Klinker, F., Liebetanz, D., Salinas-Riester, G., Wiltfang, J., Klafki, H. W., & Wirths, O. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.65 · Cited by 78
Cited by
Role of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370
Rom, S., Zuluaga-Ramirez, V., Gajghate, S., Seliga, A., Winfield, M., Heldt, N. A., Kolpakov, M. A., Bashkirova, Y. V., Sabri, A. K., & Persidsky, Y. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1195-5 · Cited by 330
Tang, A. S., Oskotsky, T., Havaldar, S., Mantyh, W. G., Bicak, M., Solsberg, C. W., Woldemariam, S., Zeng, B., Hu, Z., Oskotsky, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28273-0 · Cited by 45
Identification and Experimental Validation of Marker Genes between Diabetes and Alzheimer’s Disease
Huang, C., Wen, X., Xie, H., Hu, D., & Li, K. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8122532 · Cited by 15
Metadata
- Authors
- Goldwaser, E. L., Acharya, N. K., Sarkar, A., Godsey, G., & Nagele, R. G.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-09-06
- Volume
- 54
- Issue
- 2
- Pages
- 445-456
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2491183319
- Cited by
- 65
- References
- 22
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.